Amin Faisal Mohammad, Linnet Thor, Cullum Christopher Kjaer, Do Thien Phu, Younis Samaira
Department of Neurology, Danish Headache Center, Copenhagen University Hospital- Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
J Headache Pain. 2025 Jul 1;26(1):152. doi: 10.1186/s10194-025-02087-z.
While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patients with chronic migraine who experienced adverse events on erenumab.
Data was obtained from adult patients with chronic migraine who failed erenumab treatment due to lack of tolerability and subsequently received at least three months of treatment with fremanezumab after discontinuing erenumab. Adverse events were recorded before and after the switch.
In total, 94 patients were enrolled, with a median age of 50 years. Hereof, 29 (31%) participants experienced treatment-emergent adverse events during the study period after switching from erenumab to fremanezumab. The most prevalent adverse event on erenumab before switching was constipation ( = 74, 79%), which reduced to only 12% ( = 9) of patients who switched to fremanezumab. There was no treatment discontinuation after switching to fremanezumab during the three-months study period.
Switching treatment from erenumab to fremanezumab due to adverse events is well-tolerated in patients with chronic migraine. This findings suggests a viable option to switch between treatments. Further studies are needed to assess the efficacy of switching between these treatments.
虽然erenumab和fremanezumab是预防偏头痛的有效治疗方法，但尚不清楚经历与erenumab相关不良事件的患者是否能耐受fremanezumab。本研究评估了在erenumab上出现不良事件的慢性偏头痛患者从erenumab转换为fremanezumab的耐受性。
数据来自因耐受性不足而erenumab治疗失败的成年慢性偏头痛患者，这些患者在停用erenumab后随后接受了至少三个月的fremanezumab治疗。在转换前后记录不良事件。
总共招募了94名患者，中位年龄为50岁。其中，29名（31%）参与者在从erenumab转换为fremanezumab后的研究期间出现了治疗中出现的不良事件。转换前erenumab上最常见的不良事件是便秘（n = 74，79%），而转换为fremanezumab的患者中这一比例仅降至12%（n = 9）。在为期三个月的研究期间，转换为fremanezumab后没有出现治疗中断的情况。
因不良事件从erenumab转换为fremanezumab的治疗在慢性偏头痛患者中耐受性良好。这一发现提示了一种可行的治疗间转换选择。需要进一步研究来评估这些治疗间转换的疗效。
